New treatments, new targets and new biomarkers: Dr Keith Stewart of the Mayo Clinic, Minnesota, talks to the limbic about how the treatment of relapsed refractory multiple myeloma has been transformed and the exciting developments ahead.
This article was sponsored by Amgen, which has no control over editorial content. The content is entirely independent and based on published studies and experts’ opinions, the views expressed are not necessarily those of Amgen.